<DOC>
	<DOCNO>NCT00093548</DOCNO>
	<brief_summary>RATIONALE : Vaccines make DNA gene-modified virus may make body build immune response kill tumor cell . Giving booster vaccination may make strong immune response prevent delay recurrence liver cancer . PURPOSE : This phase I/II trial study side effect best dose vaccine therapy see well work treat patient stage II , stage IIIA , stage IIIB , stage IVA liver cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage II , Stage IIIA , Stage IIIB , Stage IVA Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose adjuvant vaccination comprise alpha fetoprotein ( AFP ) plasmid DNA sargramostim ( GM-CSF ) plasmid DNA follow AFP adenoviral vector boost patient HLA-A*0201-expressing stage II-IVA hepatocellular carcinoma . Secondary - Determine optimal biological dose regimen , define generation AFP-specific immunity , patient . - Determine disease-free survival patient treat regimen . OUTLINE : This dose-escalation study alpha fetoprotein ( AFP ) adenoviral vector boost . Patients receive vaccination comprise AFP plasmid DNA sargramostim ( GM-CSF ) plasmid DNA intramuscularly ( IM ) day 1 , 30 , 60 absence unacceptable toxicity . Patients receive boost immunization comprise AFP adenoviral vector IM intradermally day 90 . Cohorts 3-6 patient receive escalate dos AFP adenoviral vector boost maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow monthly 3 month every 6 month thereafter . PROJECTED ACCRUAL : A total 3-25 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma Stage IIIVA disease No active disease local regional therapy ( e.g. , surgical resection , radiofrequency ablation , cryoablation , ethanol injection ) Serum alpha fetoprotein &gt; upper limit normal HLAA*0201 positive DNA subtyping PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Hemoglobin &gt; 9.0 g/dL ( transfusion independent ) Platelet count &gt; 50,000/mm^3 Absolute neutrophil count &gt; 1,000/mm^3 Hepatic Child Pugh class A B liver function Hepatitis B C viral infection allow Renal Not specify Cardiovascular No New York Heart Association class III IV cardiac insufficiency No coronary artery disease Immunologic HIV negative No acute viral , bacterial , fungal infection require therapy No allergy study agents No history opportunistic infection No high serum titer neutralize antiadenoviral antibody No congenital acquire condition result inability generate immune response Other Not pregnant Negative pregnancy test Fertile patient must use effective doublemethod ( include barrier method ) contraception No condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 30 day since prior chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy At least 30 day since prior steroid therapy No concurrent steroid therapy , include corticosteroid Radiotherapy Not specify Surgery See Disease Characteristics No prior organ allograft Other At least 2 week since prior therapy acute infection No concurrent immunosuppressive therapy No concurrent cyclosporine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
</DOC>